期刊文献+

RP-HPLC法测定替勃龙原料药有关物质及含量 被引量:1

RP-HPLC determination of content and related substances of tibolone
原文传递
导出
摘要 目的:建立RP-HPLC法测定替勃龙原料药的有关物质及含量。方法:采用Promosil-C18柱(250 mm×4.6 mm,5μm),以甲醇-乙腈-水(50:30:20)为流动相,流速1.0 mL·min-1,检测波长204 nm,柱温为室温,进样量10μL。结果:替勃龙浓度在0.5~250.0μg·mL-1范围内呈良好的线性关系(r=0.9999);以主成分自身对照法检测供试品中的相关物质,线性范围是0.2~20.0μg·mL-1(r=0.9994);检出限为0.05μg·mL-1。替勃龙低、中、高浓度平均加样回收率(n=3)分别为99.7%,99.9%,99.9%;RSD分别为0.2%,0.2%,0.1%。结论:本方法简便、灵敏,重复性好,结果准确可靠,可用于替勃龙原料药有关物质及含量的检测与分析以及质量控制。 Objective:To establish an RP-HPLC method to determine the related substances of tibolone and its content.Method:The assay was conducted on a Promosil-C18 column(250 mm×4.6 mm,5 μm)with methanol-acetonitrile-water(50:30:20)as mobile phase at the flow rate of 1.0 mL·min-1,and the detection wavelength was 204 nm.The column temperature was room temperature and the injection volume was 10 μL.Results:The linear concentration range of tibolone was 0.5-250.0 μg·mL-1 with the correlation coefficient of 0.9999.It is detected the related substances with the method of the composition of the product itself,its linear concentration range was 0.2-20.0 μg·mL-1 with the coefficient of 0.9994,the detection limit was 0.05 μg·mL-1.The recoveries(n=3)of low,medium,and high concentration were 99.7%,99.9%,99.9%,and the RSDs were 0.2%,0.2%,0.1%,respectively.Conclusion:The method is simple,sensitive and reproducible,the results are accurate and reliable.It may be practical value for the quality control of tibolone and its related substances.
出处 《药物分析杂志》 CAS CSCD 北大核心 2012年第6期994-997,共4页 Chinese Journal of Pharmaceutical Analysis
基金 河北省科技攻关资助项目(05276101D-88) 河北教育厅科学研究计划项目(2009315) 河北省卫生厅医学科学研究重点课题计划项目(20090570) 河北省中医药管理局科研计划课题(2008072)
关键词 高效液相色谱法 替勃龙 原料药 有关物质 含量测定 对照法 质量控制 HPLC tibolone bulk drug related substance assay counter point quality control
  • 相关文献

参考文献5

二级参考文献17

  • 1程国钧,刘建立.绝经后妇女雌激素替代治疗[J].中华妇产科杂志,1995,30(2):123-127. 被引量:150
  • 2陶惠兰.新型性腺激素Livial治疗妇女更年期综合征的临床研究[J].中国生化药物杂志,1996,17(3):129-131. 被引量:3
  • 3[2]Beral V,Bull D,Doll R,et al.Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer[J].Lancet,1997,350:1047-1059. 被引量:1
  • 4[3]Susan RD.Menopause:new therapies[J].MJA,2003,178 (12):634-637. 被引量:1
  • 5[5]Yand TS,Tsan SH,Chen CR,et al.Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women[J].Zhonghua Yi Xue za zhi(Taipei).1999,62(5):308-315. 被引量:1
  • 6[7]Palomba S,Picarbo C,Morelli M,et al.Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy[J].Maturitas.2003,45(4):267-273. 被引量:1
  • 7MILNER M,SINNOTT M,TOMMY M,et al.A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin[J].Obstet Gynecol,1996,87(4):593-599. 被引量:1
  • 8BJARNASON N H,BJARNASON K,HAARBO J.Tibolone:prevention of bone loss in late postmenopausal women[J].J Clin Endocrinol Metab,1996,81 (7):5419-5422. 被引量:1
  • 9CHERITE G,KLOOSTERBOER H J,PASQUALIN J R.Effect of tibolone and its metabolites on estrons sulfatase activity in MCF-7and T47D mammary cancer cells[J].Anticancer Pes,1997,17(1A):135-140. 被引量:1
  • 10KENEMANS P,SCHEELE F,BURGER C W.Hormone replacement therapy and breast cancer morbidity,mortality and recurrence[J].Eur J Obstet Gynecol Reprod Biol,1997,71 (2):199-203. 被引量:1

共引文献9

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部